(Q44230026)

1 December 2017

Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans (English)

1 reference

1 December 2017

1 reference

Shinji Furuta

1

1 reference

1 December 2017

Clair Smart

2

1 reference

1 December 2017

Andrew Hackett

3

1 reference

1 December 2017

Rajdeep Benning

4

1 reference

1 December 2017

Steve Warrington

5

1 reference

1 December 2017

language of work or name

English

0 references

publication date

18 October 2012

1 reference

1 December 2017

1 reference

1 December 2017

43

1 reference

1 December 2017

5

1 reference

1 December 2017

432-442

1 reference

Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events

1 December 2017

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2012.731618

Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2012.731618

Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2012.731618

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2012.731618

DPP-4 inhibitors in the treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2012.731618

Membrane transporters in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2012.731618

Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2012.731618

Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2012.731618

Tissue distribution of human acetylcholinesterase and butyrylcholinesterase messenger RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2012.731618

Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2012.731618

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2012.731618

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2012.731618

Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2012.731618

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2012.731618

Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2012.731618

Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2012.731618

Current management strategies for coexisting diabetes mellitus and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2012.731618

Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2012.731618

Global estimates of the prevalence of diabetes for 2010 and 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2012.731618

Type 2 diabetes: principles of pathogenesis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2012.731618

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2012.731618

Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2012.731618

Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2012.731618

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00498254.2012.731618

10.3109/00498254.2012.731618

21 January 2018

Identifiers

DOI

1 reference

1 December 2017

1 reference